cc-5013
Amyloid Plaque
St. Joseph's Hospital and Medical Center, PhoenixPhase 2Active
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Amyloid Plaque cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Donanemab Eli Lilly and Company | Phase 3 | B |
Aci-24.060 AC Immune SA | Phase 1/2 | CCC |
Same molecule, other indications
cc-5013 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →